Drug Profile
Melanoma vaccine - GlaxoSmithKline
Alternative Names: MelacineLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Cancer vaccines
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malignant melanoma
Most Recent Events
- 08 Dec 2003 Melacine® is available for licensing (www.corixa.com)
- 08 Dec 2003 Discontinued - Phase-III for Malignant melanoma in USA (IM, Injection)
- 31 Jul 2002 Schering Plough has terminated its worldwide license for Melacine®